Drugs Made In America Acquisition II Corp. Unit
DMIIU
NASDAQ Global Select10.14
USD
-0.02
- -
CIK
0002040475
ISIN
KYG2851K1206
CUSIP
G2851K120
Return %
Stock
S&P500
1Y
1.50
19.01
3Y
1.50
65.48
5Y
1.50
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Roger Bendelac
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 420 Lexington Avenue New York NY United States of America 33301
- IPO Date
- Sep 25, 2025
- CIK
- 0002040475
- Website
- dmaacorp.com
- Similar Companies
- Business
- Drugs Made In America Acquisition II Corp. is a blank check company incorporated in the Cayman Islands in 2024 and headquartered at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, Florida; the company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses, primarily targeting the pharmaceutical industry to promote on-shoring of domestic manufacturing for critical drugs and mitigate U.S. supply chain risks from concentrated foreign production. Each unit (Nasdaq: DMIIU) consists of one ordinary share and one right to receive one-tenth of an ordinary share upon completion of an initial business combination; upon separation, ordinary shares and rights trade under symbols DMII and DMIIR, respectively, with sponsor-led private placement units providing additional funding flexibility. The company completed a $500 million initial public offering of 50 million units at $10.00 per unit on September 26, 2025, underwritten by Cantor Fitzgerald & Co. with a 45-day over-allotment option for 7.5 million units, concurrently closing a $12 million private placement of 1.2 million units purchased by sponsor Drugs Made In America Acquisition II LLC and Cantor Fitzgerald; as of September 30, 2025, $500.1 million resides in trust, funding the search for a target within 24 months or triggering liquidation, amid ongoing general and administrative costs and no identified business combination target to date.
DMIIU (NASDAQ:DMIIU) Shares Down 0.2% – Here’s Why
U.S. IPO Weekly Recap: One Small Debut As More Names Join The Pipeline